Mobile Site ›

The Classic Myeloproliferative Neoplasms

Optimizing Laboratory Testing for Hematologic Disorders Series

Conclusion #2 — JAK2 Exon 12 Sequencing

Slide 20

October 2011

Thus, our second conclusion of the day: JAK2 V617F mutation assay is the preferred screening assay for JAK2 mutations. Second of all, JAK2 exon 12 sequencing will frequently be inappropriately ordered instead of the V617F as physicians are not aware of the differences between the various JAK2 assays. And finally, sequencing studies should be reserved for those patients who are negative for JAK2 V617F and have CBC and serum erythropoietin findings suggestive of polycythemia vera.

Conclusion #2 — JAK2 Exon 12 Sequencing


Jump to section: